CL2024000370A1 - Composiciones y métodos para el tratamiento de cáncer. - Google Patents

Composiciones y métodos para el tratamiento de cáncer.

Info

Publication number
CL2024000370A1
CL2024000370A1 CL2024000370A CL2024000370A CL2024000370A1 CL 2024000370 A1 CL2024000370 A1 CL 2024000370A1 CL 2024000370 A CL2024000370 A CL 2024000370A CL 2024000370 A CL2024000370 A CL 2024000370A CL 2024000370 A1 CL2024000370 A1 CL 2024000370A1
Authority
CL
Chile
Prior art keywords
compositions
treatment
cancer
methods
beta
Prior art date
Application number
CL2024000370A
Other languages
English (en)
Spanish (es)
Inventor
Chatterjee Subroto
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of CL2024000370A1 publication Critical patent/CL2024000370A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91091Glycosyltransferases (2.4)
    • G01N2333/91097Hexosyltransferases (general) (2.4.1)
    • G01N2333/91102Hexosyltransferases (general) (2.4.1) with definite EC number (2.4.1.-)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2024000370A 2021-08-10 2024-02-06 Composiciones y métodos para el tratamiento de cáncer. CL2024000370A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163231694P 2021-08-10 2021-08-10

Publications (1)

Publication Number Publication Date
CL2024000370A1 true CL2024000370A1 (es) 2024-10-25

Family

ID=85201061

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000370A CL2024000370A1 (es) 2021-08-10 2024-02-06 Composiciones y métodos para el tratamiento de cáncer.

Country Status (9)

Country Link
US (1) US20240360247A1 (https=)
EP (1) EP4384220A4 (https=)
JP (1) JP2024533998A (https=)
CN (1) CN118139642A (https=)
AU (1) AU2022326557A1 (https=)
CA (1) CA3225489A1 (https=)
CL (1) CL2024000370A1 (https=)
CO (1) CO2024001405A2 (https=)
WO (1) WO2023019186A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025171394A1 (en) * 2024-02-09 2025-08-14 The Johns Hopkins University Compositions and methods for treatment of cancer
CN119861198B (zh) * 2025-01-02 2025-09-16 哈尔滨脉图精准技术有限公司 用于区分早期肺癌与肺炎的血浆代谢标志物组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070085232A (ko) * 2004-08-20 2007-08-27 더 존스 홉킨스 유니버시티 혈관신생 치료방법
US11339213B2 (en) * 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
PE20181326A1 (es) * 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
US20200181264A1 (en) * 2017-08-11 2020-06-11 City Of Hope Bispecific antigen-binding molecule
WO2019236722A1 (en) * 2018-06-05 2019-12-12 Chatterjee Subroto B Inhibitors of glycosphingolipid synthesis and methods of use

Also Published As

Publication number Publication date
EP4384220A4 (en) 2025-06-18
JP2024533998A (ja) 2024-09-18
AU2022326557A1 (en) 2024-01-25
CA3225489A1 (en) 2023-02-16
CO2024001405A2 (es) 2024-07-29
WO2023019186A3 (en) 2023-08-03
US20240360247A1 (en) 2024-10-31
WO2023019186A2 (en) 2023-02-16
EP4384220A2 (en) 2024-06-19
CN118139642A (zh) 2024-06-04

Similar Documents

Publication Publication Date Title
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
NZ784224A (en) Parp1 inhibitors
PH12020500033A1 (en) Macrocyclic compounds and uses thereof
CL2024000370A1 (es) Composiciones y métodos para el tratamiento de cáncer.
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
GEAP202115183A (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2024012801A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
PH12017502002A1 (en) 5`-substituted nucleoside analogs
MX389683B (es) Composiciones terapeuticas, combinaciones y metodos de uso
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CR20240296A (es) Inhibidores parp1
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX374946B (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil)]-fosfato) para usarse en el tratamiento de cáncer para hacer blanco en las células de cáncer.
BR112019011199A2 (pt) método para tratar um indivíduo que tem um câncer de próstata e kits
PH12017501879A1 (en) Methods for treating cancer
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
MX2022007626A (es) Combinaciones.
CL2024001535A1 (es) Quinolinas y azaquinolinas como inhibidores de cd38
PE20210109A1 (es) Moduladores de la expresion de irf4
MX2025002424A (es) Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same